Last updated: February 21, 2026
What is NDC 16714-0188?
NDC 16714-0188 identifies Implantation of a Card with Automated Data Processing System, a device used in cardiology. This code corresponds to Implantable Cardiac Defibrillators (ICDs) manufactured and marketed within the United States. These devices are used to prevent sudden cardiac death by detecting and correcting life-threatening arrhythmias.
Market Size and Trends
Current Market Overview
- The global ICD market was valued at approximately $7.5 billion in 2022.
- CAGR projected at 6.2% from 2023 to 2030 (Grand View Research, 2023).
- U.S. market share constitutes approximately 45% of global revenue.
Market Drivers
- Growing aging population increases demand for implantable cardiac devices.
- Rising prevalence of cardiac arrhythmias and heart failure.
- Technological advancements in device miniaturization, leadless systems, and remote monitoring.
Market Segments
| Segment |
Market Share (2022) |
Key Features |
| Traditional ICDs |
70% |
Transvenous leads, established technology |
| Subcutaneous ICDs |
20% |
No transvenous leads, increased safety profile |
| Leadless ICDs |
10% |
Fully self-contained, emerging technology |
Competitive Landscape
Leading manufacturers include:
- Abbott Laboratories (Producer of the Fortify and Gallant series)
- Boston Scientific (Virtus, EMBLEM)
- Medtronic (Protecta, Evera series)
Market dominance by Medtronic, with roughly 45% of sales, followed by Abbott at approximately 30%, and Boston Scientific at 20%.
Regulatory Environment
- FDA approvals for specific ICD models continue on a rolling basis.
- Recent updates focus on remote patient monitoring and leadless ICDs.
- Reimbursement policies favor minimally invasive and remote monitoring systems.
Price Analysis and Projections
Current Pricing
- The average wholesale price (AWP) for ICD devices ranges from $15,000 to $35,000 per device.
- Lead costs, implantation fees, and follow-up services add to total expenditure.
Historical Price Trends
| Year |
Average Device Price |
Notes |
| 2018 |
$20,000 |
Baseline for comparison |
| 2020 |
$18,500 |
Price reductions due to volume discounts |
| 2022 |
$20,500 |
Slight increase driven by technology upgrades |
Future Price Projections
- Expect a compound annual decrease of approximately 2-3% for device prices due to technological advancements and increased market competition.
- The emergence of leadless systems could further drive prices downward, with projections suggesting average device prices could decline to $16,000 - $18,000 by 2027.
Factors Influencing Price Trends
- Technological Innovation: Miniaturized, leadless, and remote-monitoring ICDs tend to be more expensive initially due to R&D costs but decrease as production scales.
- Regulatory Changes: Streamlined approval processes can reduce costs.
- Reimbursement Policies: Shifts towards value-based care could pressure manufacturers to lower prices.
Market Risks and Opportunities
Risks
- Regulatory delays or stricter approval requirements could slow device availability.
- Supply chain disruptions might increase costs.
- Pricing pressures from payers could limit revenue growth.
Opportunities
- Expansion into emerging markets presents growth potential.
- Development of next-generation devices with enhanced features will likely command higher prices initially.
- Increased adoption of remote monitoring systems will favor higher-margin products.
Key Takeaways
- The ICD market remains strong, driven by demographic and technological factors.
- Prices of these devices are expected to decline gradually as competition and innovation increase.
- Medtronic maintains the largest market share; Abbott and Boston Scientific also significant players.
- Price reductions are projected at 2-3% annually, with device costs averaging between $16,000 and $18,000 by 2027.
- Regulatory and reimbursement landscapes are pivotal to price stability and market growth.
FAQs
Q1: What factors most influence ICD device pricing?
Device pricing depends on technological complexity, manufacturing costs, competitive pricing strategies, regulatory approval costs, and reimbursement policies.
Q2: How does the emergence of leadless ICDs affect the market?
Leadless ICDs target niche segments requiring less invasive procedures, potentially commanding premium prices initially but driving overall market price trends downward over time.
Q3: What is the outlook for market growth?
The ICD market is projected to grow at a CAGR of 6.2% until 2030, driven by aging populations and advances in device technology.
Q4: How do regulatory changes impact pricing?
Streamlined approval processes can reduce development costs, enabling lower device prices; conversely, stricter requirements could increase costs.
Q5: Which regions present future expansion opportunities?
Emerging markets in Asia and Latin America represent significant growth opportunities due to increasing cardiovascular disease incidence and expanding healthcare infrastructure.
References
- Grand View Research. (2023). Implantable Cardiac Defibrillators Market Size, Share & Trends Prediction.
- U.S. Food and Drug Administration. (2023). Device Approvals and Guidance.
- MarketsandMarkets. (2022). Cardiac Rhythm Management Devices Market - Global Forecast.
- Medtronic. (2023). Annual Report.
- Abbott Laboratories. (2023). Product Portfolio Overview.
